Scientific publications

Expansion of Tumor-Infiltrating CD8 + T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy

Jul 1, 2017 | Magazine: Cancer Research

Sarita M Fernandez-Poma  1   2 , Diego Salas-Benito  2   3 , Teresa Lozano  1   2 , Noelia Casares  1   2 , Jose-Ignacio Riezu-Boj  2   4 , Uxua Mancheño  1   2 , Edurne Elizalde  1   2 , Diego Alignani  2   5 , Natalia Zubeldia  1   2 , Itziar Otano  1   2 , Enrique Conde  1   2 , Pablo Sarobe  1   2 , Juan Jose Lasarte  1   2 , Sandra Hervas-Stubbs  6   2


Abstract

Recent studies have found that tumor-infiltrating lymphocytes (TIL) expressing PD-1 can recognize autologous tumor cells, suggesting that cells derived from PD-1+ TILs can be used in adoptive T-cell therapy (ACT).

However, no study thus far has evaluated the antitumor activity of PD-1-selected TILs in vivo In two mouse models of solid tumors, we show that PD-1 allows identification and isolation of tumor-specific TILs without previous knowledge of their antigen specificities. Importantly, despite the high proportion of tumor-reactive T cells present in bulk CD8 TILs before expansion, only T-cell products derived from sorted PD-1+, but not from PD-1- or bulk CD8 TILs, specifically recognized tumor cells.

The fold expansion of PD-1+ CD8 TILs was 10 times lower than that of PD-1- cells, suggesting that outgrowth of PD-1- cells was the limiting factor in the tumor specificity of cells derived from bulk CD8 TILs. The highly differentiated state of PD-1+ cells was likely the main cause hampering ex vivo expansion of this subset. Moreover, PD-1 precisely identified marrow-infiltrating, myeloma-specific T cells in a mouse model of multiple myeloma. In vivo, only cells expanded from PD-1+ CD8 TILs contained tumor progression, and their efficacy was enhanced by PDL-1 blockade.

Overall, our data provide a rationale for the use of PD-1-selected TILs in ACT. Cancer Res; 77(13); 3672-84. ©2017 AACR.

CITA DEL ARTÍCULO  Cancer Res. 2017 Jul 1;77(13):3672-3684.  doi: 10.1158/0008-5472.CAN-17-0236. Epub 2017 May 18.

Our authors

Dr. Teresa Lozano Moreda
Researcher | Principal Investigator Immunology and Immunotherapy Research Program
Uxua Mancheño Ujué
Edurne Elizalde Agurruza
Diego Alignani
Laboratory technician Cytometry Platform
Enrique Conde Gallastegi
Dr. Sandra Hervás Stubbs
Researcher | Principal Investigator Immunology and Immunotherapy Research Program